Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Group 1 - Alector Inc. is focusing on its ABC platform, which has been led by Eric Brown for the past 7 years [2] - The company has one non-ABC-enabled program, AL101, which is undergoing an interim futility analysis in the first half of the year by an independent monitoring committee [2][3] - Alector's lead antibody candidate is an Aß antibody enabled by the ABC platform, and its lead enzyme candidate is a GCase enzyme, both of which are progressing towards IND [3] Group 2 - The company is also introducing its siRNA platform, which utilizes blood-brain barrier technology, highlighted by the TAU ABC molecule [4] - Additional lead or follow-on molecules within the siRNA platform will be identified during the presentation [4]